Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 1/20 | 0.55 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.39 |
| ▸ | PAOX | Q6QHF9 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | KDM4A | O75164 | 1/20 | 0.32 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | PRMT3 | O60678 | 1/20 | 0.30 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.30 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.30 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.30 |
| ▸ | PRMT8 | Q9NR22 | 1/20 | 0.30 |
| ▸ | HTR1B | P28222 | 1/20 | 0.30 |
| ▸ | HTR2A | P28223 | 1/20 | 0.30 |
| ▸ | HRH1 | P35367 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5142057 | 1.00 | EPHX1 (0.55) | EPHX1SIGMAR1PAOXL3MBTL1KDM4A | |
| SCHEMBL6235646 | 1.00 | EPHX1 (0.55) | EPHX1SIGMAR1PAOXL3MBTL1KDM4A | |
| SCHEMBL16892582 | 1.00 | EPHX1 (0.55) | EPHX1SIGMAR1PAOXL3MBTL1KDM4A | |
| SCHEMBL7453221 | 1.00 | EPHX1 (0.55) | EPHX1SIGMAR1PAOXL3MBTL1KDM4A | |
| SCHEMBL198272 | 1.00 | — | — | |
| SCHEMBL997426 | 1.00 | — | — | |
| SCHEMBL5073915 | 1.00 | EPHX1 (0.55) | EPHX1SIGMAR1PAOXL3MBTL1KDM4A | |
| SCHEMBL5249016 | 1.00 | EPHX1 (0.55) | EPHX1SIGMAR1PAOXL3MBTL1KDM4A | |
| SCHEMBL5246477 | 1.00 | EPHX1 (0.55) | EPHX1SIGMAR1PAOXL3MBTL1KDM4A | |
| SCHEMBL434754 | 0.97 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 65 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1813636-A1 | Polyamine analogs that activate antizyme frameshifting | MediQuest Therapeutics, Inc. (US) | 2007-08-01 | — | — | EP | claimed |
| EP-1730100-A1 | POLYAMINE ANALOGS THAT ACTIVATE ANTIZYME FRAMESHIFTING | MediQuest Therapeutics, Inc. (US) | 2006-12-13 | — | — | EP | claimed |
| WO-2005105729-A1 | POLYAMINE ANALOGS THAT ACTIVATE ANTIZYME FRAMESHIFTING | MEDIQUEST THERAPEUTICS, INC. (US) | 2005-11-10 | — | — | WO | claimed |
| US-20040209926-A1 | Polyamine analogs that activate antizyme frameshifting | MEDIQUEST THERAPEUTICS, INC. | 2004-10-21 | — | — | US | claimed |
| US-20040058954-A1 | Polyamine analogs that activate antizyme framshifting | MEDIQUEST THERAPEUTICS, INC. | 2004-03-25 | — | — | US | claimed |
| EP-1379577-A1 | CONTROLLING SOLAR RADIATION IN SAFETY GLASS LAMINATES | Solutia Inc. (US) | 2004-01-14 | — | — | EP | claimed |
| WO-2002077081-A1 | CONTROLLING SOLAR RADIATION IN SAFETY GLASS LAMINATES | SOLUTIA, INC. (US) | 2002-10-03 | — | — | WO | claimed |
| EP-3831372-A1 | MITOGUAZONE FOR PREVENTING THE RELAPSE OR THE PROGRESSION OF MULTIPLE SCLEROSIS | Pathologica LLC (US) | 2021-06-09 | — | — | EP | disclosed |
| US-10350178-B2 | Methods and compositions for treatment of demyelinating diseases | PATHOLOGICA LLC (US) | 2019-07-16 | — | — | US | disclosed |
| EP-3473247-A1 | COMPOSITION FOR ORAL DELIVERY COMPRISING MGBG FOR USE IN TREATING MULTIPLE SCLEROSIS | Pathologica LLC (US) | 2019-04-24 | — | — | EP | disclosed |
| US-20180360783-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF DEMYELINATING DISEASES | PATHOLOGICA LLC | 2018-12-20 | — | — | US | disclosed |
| EP-2453886-B1 | PHARMACEUTICAL FOR ORAL DELIVERY COMPRISING MGBG AND METHODS OF TREATING DISEASE | PATHOLOGICA LLC (US) | 2018-12-12 | — | — | EP | disclosed |
| EP-2894685-B1 | BENZOTHIENOBENZOTHIOPHENE DERIVATIVE, ORGANIC SEMICONDUCTOR MATERIAL, AND ORGANIC TRANSISTOR | DAINIPPON INK & CHEMICALS (JP) | 2018-10-31 | — | — | EP | disclosed |
| US-5646123-A | Time dependent administration of oligosaccharide glycosides related to blood group determinants having a type I or type II core structure in reducing inflammation in a sensitized mammal arising form exposure to an antigen | ALBERTA RESEARCH COUNCIL (CA) | 1997-07-08 | — | — | US | disclosed |
| EP-0589933-B1 | METHODS FOR THE ENZYMATIC SYNTHESIS OF ALPHA-SIALYLATED OLIGOSACCHARIDE GLYCOSIDES | GLYCOMED INC (US) | 1997-02-12 | — | — | EP | disclosed |
| EP-0650492-A1 | REDUCING INFLAMMATION BY TIME DEPENDENT ADMINISTRATION OF OLIGOSACCHARIDES GLYCOSIDES RELATED TO BLOOD GROUP DETERMINANTS | ALBERTA RESEARCH COUNCIL (CA) | 1995-05-03 | — | — | EP | disclosed |
| US-5352670-A | Methods for the enzymatic synthesis of alpha-sialylated oligosaccharide glycosides | ALBERTA RESEARCH COUNCIL (CA) | 1994-10-04 | — | — | US | disclosed |
| EP-0589933-A1 | METHODS FOR THE ENZYMATIC SYNTHESIS OF ALPHA-SIALYLATED OLIGOSACCHARIDE GLYCOSIDES. | ALBERTA RES COUNCIL (CA) | 1994-04-06 | — | — | EP | disclosed |
| WO-1993024505-A1 | REDUCING INFLAMMATION BY TIME DEPENDENT ADMINISTRATION OF OLIGOSACCHARIDES GLYCOSIDES RELATED TO BLOOD GROUP DETERMINANTS | ALBERTA RESEARCH COUNCIL (CA) | 1993-12-09 | — | — | WO | disclosed |
| WO-1992022661-A1 | METHODS FOR THE ENZYMATIC SYNTHESIS OF ALPHA-SIALYLATED OLIGOSACCHARIDE GLYCOSIDES | ALBERTA RESEARCH COUNCIL (CA) | 1992-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040209926-A1 | Polyamine analogs that activate antizyme frameshifting | ODC1, SRM, OTC | EPHX1 2879/4885SIGMAR1 1054/4885PAOX 895/4885 |
| US-20040058954-A1 | Polyamine analogs that activate antizyme framshifting | ODC1, SRM, SMS | EPHX1 2728/4885SIGMAR1 1677/4885PAOX 569/4885 |
| US-20180360783-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF DEMYELINATING DISEASES | PMP22, MAG, GMFG | EPHX1 1817/4885SIGMAR1 4540/4885PAOX 1624/4885 |
| US-10350178-B2 | Methods and compositions for treatment of demyelinating diseases | PMP22, MAG, GMFG | EPHX1 1817/4885SIGMAR1 4540/4885PAOX 1624/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.